GAVRETO ®(pralsetinib) capsules clinical trials

A multi-center, open-label, drug-drug interaction study to evaluate the effect of pralsetinib (Gavreto) on the pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 substrates, and hormones estradiol/norethisterone acetate in patients with advanced or metastatic solid tumors.

This study looks at how a cancer medicine called Gavreto interacts with other medicines and hormones in people with advanced solid tumours. Researchers want to understand if Gavreto affects how other drugs work in the body.